EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY 4.0

Renal Denervation Effects on Blood Pressure in Resistant and Uncontrolled Hypertension: A Meta‐Analysis of Sham‐Controlled Randomized Clinical Trials

Hamidreza Soleimani, Babak Sattartabar, Bahar Parastooei, Reza Eshraghi, Roozbeh Nazari, Soroush Najdaghi, Sara Hobaby, Ali Etemadi, Mehrdad Mahalleh, Maryam Taheri, Adrian V Hernandez iD, Toshiki Kuno und 8 weitere

Clinical Cardiology · 2025

DOI: 10.1002/clc.70104 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Clinical Cardiology, 2025. Verfasst von Hamidreza Soleimani und 19 weiteren Autor:innen. Beteiligte Einrichtung: Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Blood Pressure, Hypertension, Kidney, Sympathectomy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although some guidelines recommend Renal denervation (RDN) as an alternative to anti‐HTN medications, there are concerns about its efficacy and safety. We aimed to evaluate the benefits and harms of RDN in a systematic review and meta‐analysis of sham‐controlled randomized clinical trials (RCT).

Methods

Databases were searched until September 10th, 2024, to identify RCTs evaluating RDN for treating URH versus sham control. The primary outcomes were the change in office and ambulatory 24‐h systolic (SBP) and diastolic blood pressure (DBP). Secondary outcomes were changes in daytime and nighttime SBP and DBP, home BP, number of anti‐HTN drugs, and related complications. Mean differences (MD) and relative risks (RR) described the effects of RDN on BP and complications, respectively, using random effects meta‐analyses. GRADE methodology was used to assess the certainty of evidence (COE).

Results

We found 16 included sham‐controlled RCTs [RDN ( n = 1594) vs. sham ( n = 1225)]. RDN significantly reduced office SBP (MD −4.26 mmHg, 95% CI: −5.68 to −2.84), 24 h ambulatory SBP (MD −2.63 mmHg), office DBP (MD −2.15 mmHg), 24‐h ambulatory DBP (MD −1.27 mmHg), and daytime SBP and DBP (MD −3.29 and 2.97 mmHg), compared to the sham. The rate of severe complications was low in both groups (0%–2%). The heterogeneity was high among most indices, and CoE was very low for most outcomes.

Conclusion

RDN significantly reduced several SBP and DBP outcomes versus sham without significantly increasing complications. This makes RDN a potentially effective alternative to medications in URH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood PressureHypertensionKidneySympathectomyHumansAntihypertensive AgentsRandomized Controlled Trials as TopicTreatment Outcome

Stichwörter der Autor:innen

cardiovascular eventsmeta‐analysisrenal denervationresistant hypertensionsham‐controlled

Substanzen

Antihypertensive Agents

Autor:innen und Institutionen

  • Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
  • Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Social Determinants of Health Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Cardiology Department, Modarres Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Science, Isfahan, Iran.
  • Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

ORCID-Profile: Adrian V Hernandez

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Soleimani, H., Sattartabar, B., Parastooei, B., Eshraghi, R., Nazari, R., Najdaghi, S., Hobaby, S., Etemadi, A., Mahalleh, M., Taheri, M., Hernandez, A. V., Kuno, T., Taheri, H., Siegel, R. J., Rader, F., Tehrani, B. N., Mandegar, M. H., Safaee, E., Ebrahimi, P., & Hosseini, K. (2025). Renal Denervation Effects on Blood Pressure in Resistant and Uncontrolled Hypertension: A Meta‐Analysis of Sham‐Controlled Randomized Clinical Trials. Clinical Cardiology. https://doi.org/10.1002/clc.70104

Vancouver

Soleimani H, Sattartabar B, Parastooei B, Eshraghi R, Nazari R, Najdaghi S, et al. Renal Denervation Effects on Blood Pressure in Resistant and Uncontrolled Hypertension: A Meta‐Analysis of Sham‐Controlled Randomized Clinical Trials. Clinical Cardiology. 2025. doi:10.1002/clc.70104

BibTeX
@article{Soleimani2025,
  author = {Soleimani, Hamidreza and Sattartabar, Babak and Parastooei, Bahar and Eshraghi, Reza and Nazari, Roozbeh and Najdaghi, Soroush and Hobaby, Sara and Etemadi, Ali and Mahalleh, Mehrdad and Taheri, Maryam and Hernandez, Adrian V and Kuno, Toshiki and Taheri, Homa and Siegel, Robert J and Rader, Florian and Tehrani, Behnam N and Mandegar, Mohammad Hossein and Safaee, Ehsan and Ebrahimi, Pouya and Hosseini, Kaveh},
  title = {Renal Denervation Effects on Blood Pressure in Resistant and Uncontrolled Hypertension: A Meta‐Analysis of Sham‐Controlled Randomized Clinical Trials},
  journal = {Clinical Cardiology},
  year = {2025},
  doi = {10.1002/clc.70104}
}
Kostenlos starten →